---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-020968"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T12:38:43.231181+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# EyePoint Q3 net product revenue $9.7M (+13% YoY); initiates two Phase 2 trials for EYP-1901; DEXYCU termination

## Summary
- Q3 net product revenue $9.7M (+13% YoY); net loss $18.4M ($0.49 diluted EPS) vs $16.7M loss prior year.
- Initiated Phase 2 DAVIO 2 (wet AMD) and Phase 2 PAVIA (NPDR) for EYP-1901; topline data expected Q4 2023.
- Final 12-month Phase 1 DAVIO data showed positive safety: 73% reduction in treatment burden, no ocular SAEs.
- DEXYCU commercialization agreement terminated effective Dec 31, 2022 due to CMS pass-through denial.
- Cash $157.3M; expect to fund operations into H2 2024.

## SEC filing metadata
- accession: 0000950170-22-020968
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017022020968/0000950170-22-020968-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017022020968/eypt-20221102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-020968
- JSON: https://secwatch.observer/filing/0000950170-22-020968.json
- Plain text: https://secwatch.observer/filing/0000950170-22-020968.txt

## Key facts
- Earnings Releases
  EyePoint, Inc. reported third quarter ended September 30, 2022 results: revenue $10.0 million, net income $18.4 million, EPS ($.49) per share.
  - Period: third quarter ended September 30, 2022
  - Revenue: $10.0 million
  - Net income: $18.4 million
  - EPS: ($.49) per share
  - Result: reported results
  source text: For the third quarter ended September 30, 2022, total net revenue was $10.0 million compared to $9.1 million for the quarter ended September 30, 2021. Net product revenue for the third quarter was $9.7 million, compared to net product revenues for the third quarter ended September 30, 2021 of $8.6 million. Net revenue from royalties and collaborations for the third quarter ended September 30, 2022 totaled $0.3 million compared to $0.5 million in the corresponding period in 2021. Operating expenses for the third quarter ended September 30, 2022 totaled $28.4 million versus $24.4 million in the prior year period, primarily driven by investment in personnel across the organization, including non-cash stock compensation, and ongoing clinical trial and development costs for EYP-1901. Non-operating expense, net, totaled $0.02 million and net loss was $18.4 million, or ($.49) per share, compared to a net loss of $16.7 million, or ($0.58) per share, for the prior year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1314102/000095017022020968/0000950170-22-020968-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.